Andersen-Tawil syndrome is an autosomal dominant potassium channelopathy characterized by episodic flaccid muscle weakness (periodic paralysis), cardiac abnormalities (ventricular arrhythmias, prolonged QT interval, and prominent U waves), and characteristic skeletal features (low set ears, ocular hypertelorism, small mandible, fifth digit clinodactyly, syndactyly, short stature, scoliosis, and broad forehead).^[@R1]^ Mutations in the *KCNJ2* gene on chromosome 17q23 are found in about 60% of the patients with Andersen-Tawil syndrome.^[@R2]^ In the absence of a genetic change in *KCNJ2*, diagnosis of Andersen-Tawil syndrome is established by the presence of well-defined clinical findings. The distinctive clinical triad of Andersen-Tawil syndrome is present in 60%--80% of patients with *KCNJ2* mutations.^[@R1],[@R2]^ *KCNJ2* encodes the pore-forming subunit of an inward-rectifying potassium channel protein, Kir2.1, helping in skeletal and cardiac muscle resting membrane potential stabilization. Mutations in this gene cause loss of function and dominant-negative suppression effects on the Kir2.1 protein, leading to disruption of the cardiac and skeletal muscle excitability.^[@R2],[@R3]^ *KCNJ2* mutations in Andersen-Tawil syndrome affect multiple tissues and results in a wide phenotypic variability causing diagnostic difficulties and delay.^[@R2]^ We describe the varied clinical characteristics of Andersen-Tawil syndrome in a Caucasian family (mother and her 2 daughters) with a rare missense mutation in *KCNJ2*.

The 42-year-old mother presented with a 15-year history of episodes of periodic paralysis affecting her upper or lower extremities. In the absence of a clear diagnosis, she was treated with systemic steroids on multiple occasions for presumed polymyositis. At the age of 34 years, during the first trimester of her first pregnancy, she had an episode of paralysis associated with hypokalemia. The weakness recovered after potassium supplementation. Her 7-year-old daughter has episodic muscle weakness, cardiac involvement with premature ventricular contractions and prominent U wave, and distinctive skeletal features while the younger daughter has only skeletal features. Both daughters had normal birth and development. The clinical features of our patients are described in the [figure](#F1){ref-type="fig"}. Targeted sequencing of the *KCNJ2* gene showed a heterozygous missense mutation (c. 575C\>T; p.Thr192Ile) in exon 2 in the mother and both daughters. The testing was based on identification of the same mutation in mother\'s 21-year-old niece who was noted to have prolonged QT interval during an evaluation for syncope. She also has short toes and syndactyly, but no reported episodic weakness. The mother\'s brother, an obligate carrier, is asymptomatic.
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(A) Clinical features of patients. ^a^Low dose extended release potassium due to history of daily muscle weakness; prophylactic acetazolamide in the peri-menstrual period as menstruation is a trigger for periodic paralysis in her. (B) Pedigree of patients. Black symbols denote family members affected with Andersen-Tawil syndrome with genetic confirmation. Patients described in this report are indicated by arrows.](NG2018008896FF1){#F1}

The missense mutation of p.Thr192Ile found in our patients was previously reported in a single Taiwanese family with Andersen-Tawil syndrome.^[@R4]^ The proband was a 35-year-old woman with typical clinical triad of Andersen-Tawil syndrome and fixed extremity and truncal weakness. In addition, she was also noted to have pyramidal tract signs and major depression. Her 8-year-old son, who was also affected with Andersen-Tawil syndrome with long-QT syndrome and characteristic skeletal features, was identified to have learning disability. Authors of the study postulated that the atypical neuropsychiatric features noted in this family expand the phenotype of Andersen-Tawil syndrome.^[@R4]^ Such clinical features (pyramidal tract signs, depression, cognitive delay, and learning disability) were not noted in our patients.

The pathogenicity of the mutation p.Thr192Ile remains unproven in vitro. This missense mutation causes replacement of the amino acid threonine by isoleucine at codon 192. The amino acid substitution is predicted to be "probably damaging" by the polymorphism phenotyping tool (Polyphen-2).^[@R5]^ The p.Thr192 residue is located in the highly conserved region of the C-terminal intracellular domain of the Kir2.1 protein emphasizing its importance during evolution.^[@R4][@R5][@R6]^ Moreover, replacement of threonine at this position by another amino acid alanine (p.Thr192Ala) has been reported to be causative for Andersen-Tawil syndrome.^[@R6],[@R7]^ We speculate that the heterozygous missense mutation affecting this highly conserved region is associated with the Andersen-Tawil syndrome phenotype in our patients. The kindred described in this report and the kindred that was previously described^[@R4]^ provide clinical evidence for pathogenicity of this rare missense mutation in *KCNJ2*. In addition, our kindred demonstrated the wide intra-familial variability in penetrance of the clinical triad seen in Andersen-Tawil syndrome.

We suggest that physicians should be aware of this rare clinical entity and its high phenotypic variability even within a family while evaluating patients with transient muscle weakness. The subtle clinical and characteristic electrocardiographic features can help with early recognition and treatment.
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